EGFR Mutation is Associated with Short Progression Free Survival in Patients with Stage III Non-Squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Park SE , Noh JM , Kim YJ , Lee HS , Cho JH , Lim SW , Ahn YC , Pyo H , Choi YL , Han J , Sun JM , Lee SH , Ahn JS , Park K , Ahn MJ 
Cancer Res Treat.2018 Jun 18 ; ():.
PubMedで表示
Google翻訳で開く
(64view , 1users)
This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT).
PMID: 29914238 [PubMed - as supplied by publisher]
PMID: 29914238 [PubMed - as supplied by publisher]
関連論文
- Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
- Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.
- Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.